Bicyclic heteroaryl compounds for use as GPR35 modulators
Bicyclic heteroaryl compounds are developed to modulate GPR35, addressing the need for novel modulators to treat disorders like proliferative, gastrointestinal, fibrotic, and inflammatory conditions by leveraging the receptor's role in inflammation and immune response.
JP2026510355APending Publication Date: 2026-04-02THIRTYFIVEBIO LIMITED
2 Cites 0 Cited by
Patent Information
- Application Number
- JP2025552078
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-08
- Filing Date
- 2024-03-07
- Publication Date
- 2026-04-02
AI Technical Summary
Technical Problem
There is a need for novel small molecule modulators of GPR35 receptors to address various disorders, including proliferative, immunological, and inflammatory disorders, as current modulators are limited and their therapeutic potential is not fully explored.
Method used
Development of bicyclic heteroaryl compounds that can modulate GPR35 function, potentially offering therapeutic benefits in treating disorders such as proliferative disorders, gastrointestinal disorders, fibrotic disorders, cardiovascular diseases, and inflammatory disorders.
Benefits of technology
The bicyclic heteroaryl compounds effectively modulate GPR35, providing therapeutic options for a range of disorders by targeting the receptor's role in inflammation, immune response, and cancer progression.
✦ Generated by Eureka AI based on patent content.
Abstract
One aspect of the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is a phenyl group or a 5- or 6-membered heteroaryl group; Ring B is absent or is phenyl, pyridinyl, pyrazidinyl, pyrazinyl, pyrimidinyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, isothiazolyl or thiazolyl; Ring C is a fused bicyclic group of formula: (AA), wherein X1 to X9 form a substituted heteroaryl group containing at least one N and at least one NH; X-Y is -(CH2) m NR 21 CO; L is a direct bond or a linker group; Z is selected from alkyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl, each of which may be substituted; each R a and each R b is independently selected from alkyl, halo, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, cyano, NR 23 COR 25 、NR 24 -SO2R 26 、(CH2) q SR 27 、(CH2) q SOR 28 、(CH2) q SO2R 29 、SO2NR 30 R 31 、(CH2) q OH、(CH2) q OR 32 、NR 33 R 34 、CONR 35 R 36 、cycloalkyl and (CH q 2)-heterocycloalkyl; R 10 、R 11 、R 21 、R 22 、R 23 and R 24 are each independently selected from H and alkyl; R 12 ~R 20 、and R 25 ~R36 Each of the following is independently selected from H, alkyl, aralkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, and cycloalkyl; each of m, n, and p is independently an integer from 0 to 4; and each of q is independently an integer from 0 to 4. Further aspects of the present invention relate to pharmaceutical compositions comprising the compounds according to the present invention and the use of the compounds in the treatment of various GPR35-related disorders. [Formula 1] TIFF2026510355000540.tif56170
Need to check novelty before this filing date? Find Prior Art